Basilea Pharmaceutica Ltd (BPMUF)
44.45
0.00 (0.00%)
USD |
OTCM |
May 17, 16:00
Basilea Pharmaceutica Total Assets (Quarterly): 206.31M for Dec. 31, 2023
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 206.31M |
| June 30, 2023 | 255.80M |
| June 30, 2023 | 255.80M |
| December 31, 2022 | 238.20M |
| June 30, 2022 | 247.36M |
| June 30, 2022 | 247.36M |
| December 31, 2021 | 270.50M |
| June 30, 2021 | 246.66M |
| June 30, 2021 | 246.66M |
| December 31, 2020 | 263.02M |
| June 30, 2020 | 207.18M |
| June 30, 2020 | 207.18M |
| December 31, 2019 | 228.57M |
| June 30, 2019 | 241.23M |
| June 30, 2019 | 241.23M |
| December 31, 2018 | 286.17M |
| June 30, 2018 | 305.81M |
| June 30, 2018 | 305.81M |
| December 31, 2017 | 360.51M |
| June 30, 2017 | 307.56M |
| June 30, 2017 | 307.56M |
| Date | Value |
|---|---|
| December 31, 2016 | 322.10M |
| June 30, 2016 | 352.81M |
| June 30, 2016 | 352.81M |
| December 31, 2015 | 403.40M |
| June 30, 2015 | 268.69M |
| June 30, 2015 | 268.69M |
| December 31, 2014 | 260.29M |
| June 30, 2014 | 307.80M |
| June 30, 2014 | 307.80M |
| December 31, 2013 | 337.77M |
| June 30, 2013 | 307.11M |
| June 30, 2013 | 307.11M |
| December 31, 2012 | 411.15M |
| June 30, 2012 | 197.25M |
| June 30, 2012 | 197.25M |
| December 31, 2011 | 252.07M |
| June 30, 2011 | 334.81M |
| December 31, 2010 | 338.64M |
| June 30, 2010 | 212.44M |
| December 31, 2009 | 199.51M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
206.31M
Minimum
Dec 2023
270.50M
Maximum
Dec 2021
240.21M
Average
246.66M
Median
Jun 2021
Total Assets (Quarterly) Benchmarks
| AC Immune SA | 185.40M |
| CRISPR Therapeutics AG | 2.439B |
| Addex Therapeutics Ltd | 5.526M |
| NLS Pharmaceutics Ltd | 1.847M |
| Molecular Partners AG | 236.15M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 218.22M |
| Shareholders Equity (Quarterly) | -11.91M |
| Debt to Equity Ratio | -11.09 |
| Current Ratio | 3.197 |
| Net Debt Paydown Yield | 6.10% |